Skip to main content
Premium Trial:

Request an Annual Quote

Nuvelo s Revenues Drop Sharply, Net Loss Decreases

NEW YORK, Feb. 6 (GenomeWeb News) - Nuvelo yesterday reported a sharp drop in revenues, along with narrowing losses, for the fourth quarter of 2003.


Nuvelo, which resulted from a merger of Hyseq and Variagenics, booked $350,000 in revenues for the quarter, down from $3.5 million a year ago.


R&D expenses decreased to $6.7 million, from $9.3 million during the year-ago period.


The company's net loss was $9.4 million, or $.12 per share, down from $16.5 million, or $.72 per share, during the same period last year.


As of Dec.31, Sunnyvale, Calif.-based Nuvelo had $34.7 million in cash, cash equivalents, short-term investments, and restricted cash.


The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.